[go: up one dir, main page]

EP0700287A1 - Medicaments d'arylation - Google Patents

Medicaments d'arylation

Info

Publication number
EP0700287A1
EP0700287A1 EP94915671A EP94915671A EP0700287A1 EP 0700287 A1 EP0700287 A1 EP 0700287A1 EP 94915671 A EP94915671 A EP 94915671A EP 94915671 A EP94915671 A EP 94915671A EP 0700287 A1 EP0700287 A1 EP 0700287A1
Authority
EP
European Patent Office
Prior art keywords
acid
compound
nitro
chloro
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94915671A
Other languages
German (de)
English (en)
Inventor
Washington Odur Ayuko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RADOPATH PHARMACEUTICALS INTERNATIONAL LIMITED
Original Assignee
RADOPATH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939310520A external-priority patent/GB9310520D0/en
Application filed by RADOPATH Ltd filed Critical RADOPATH Ltd
Priority to EP99204250A priority Critical patent/EP1016405A2/fr
Publication of EP0700287A1 publication Critical patent/EP0700287A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/06—Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/24—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having three, and only three, nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/58—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/39—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing halogen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/40—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/68—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
    • C07C63/70—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Différents agents d'arylation présentant une activité en ce qui concerne le traitement du cancer et des infections virales sont décrits. Ces composés actifs comprennent un noyau aromatique contenant au moins un groupe labile et au moins un groupe électrophile. Les composés actifs préférés comprennent les acides chlorobenzène-sulfoniques ainsi que des composés de nitrobenzène éventuellement halogénés. Dans un contexte antiviral, ces composés actifs agissent efficacement contre les infections par VIH.
EP94915671A 1993-05-21 1994-05-23 Medicaments d'arylation Ceased EP0700287A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99204250A EP1016405A2 (fr) 1993-05-21 1994-05-23 Médicaments d'arylation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939310520A GB9310520D0 (en) 1993-05-21 1993-05-21 Arylating agents
GB9310520 1993-05-21
GB9405292 1994-03-17
GB9405292A GB9405292D0 (en) 1993-05-21 1994-03-17 Arylating agents
PCT/GB1994/001126 WO1994027584A2 (fr) 1993-05-21 1994-05-23 Medicaments d'arylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP99204250A Division EP1016405A2 (fr) 1993-05-21 1994-05-23 Médicaments d'arylation

Publications (1)

Publication Number Publication Date
EP0700287A1 true EP0700287A1 (fr) 1996-03-13

Family

ID=26302926

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94915671A Ceased EP0700287A1 (fr) 1993-05-21 1994-05-23 Medicaments d'arylation

Country Status (18)

Country Link
EP (1) EP0700287A1 (fr)
JP (1) JPH08510468A (fr)
CN (1) CN1124012A (fr)
AP (1) AP9400647A0 (fr)
AU (1) AU6729794A (fr)
BG (1) BG100242A (fr)
BR (1) BR9406548A (fr)
CA (1) CA2163459A1 (fr)
CZ (1) CZ307395A3 (fr)
DZ (1) DZ1781A1 (fr)
FI (1) FI955605A7 (fr)
HU (1) HUT77764A (fr)
IL (1) IL109712A0 (fr)
MA (1) MA23202A1 (fr)
NO (1) NO954702L (fr)
OA (1) OA10196A (fr)
SK (1) SK145795A3 (fr)
WO (1) WO1994027584A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2303790A (en) * 1994-03-17 1997-03-05 Radopath Ltd Benzoic acid containing chloro and or nitro groups for cancer or viral therapy
EP0751768B1 (fr) * 1994-03-17 2000-12-27 Radopath Pharmaceuticals International Limited Agent antiviral et anticancereux
WO1996029067A1 (fr) * 1995-03-17 1996-09-26 Radopath Limited Agents antiviraux et anticancereux
JPH11507326A (ja) * 1995-03-30 1999-06-29 クロイツ、ヴェルナー 腫瘍組織の選択的治療用医薬物質
US5756548A (en) * 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
GB9615619D0 (en) * 1996-03-18 1996-09-04 Radopath Ltd Costimulation of TcR/CD3-induced T-Lymphocytes
US5955506A (en) * 1996-04-03 1999-09-21 Centaur Pharmaceuticals, Inc. Benzamides for neurodegenerative disorder treatment
RU2447889C2 (ru) 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
CA2662517A1 (fr) 2006-09-05 2008-03-13 Jerome Moore Traitement du cancer
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1283331A (en) * 1970-01-03 1972-07-26 Smith Kline French Lab Pharmaceutical compositions
US3978119A (en) * 1975-07-11 1976-08-31 Gulf Research & Development Company Process for converting stilbene or bibenzyl to nitrobenzoic acids
US4283421A (en) * 1979-12-19 1981-08-11 Ray Frank F Anti-viral treatment
US4277492A (en) * 1980-05-21 1981-07-07 The Dow Chemical Company Novel 4-bis((Phenylmethyl)amino)-benzenesulfonic acids possessing antiviral activity
US4762705A (en) * 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
CA1262864A (fr) * 1982-09-17 1989-11-14 Clarence D. Cone Methode de production d'une oncolyse
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
JPS60224619A (ja) * 1984-04-24 1985-11-09 Adeka Argus Chem Co Ltd 放射線増感剤
RO92333B1 (ro) * 1985-06-18 1987-09-01 Institutul De Cercetari Chimico-Farmaceutice Produs radiosensibilizator al celulelor tumorale
JPS6468315A (en) * 1987-09-09 1989-03-14 Yasuo Kawasaki Antipyrotic of picric acid (2,4,6-trinitrophenol)
ATE147592T1 (de) * 1990-02-05 1997-02-15 Lifescience Corp Vitamine und mineralien enthaltende nahrungszusätze
CA2036695A1 (fr) * 1990-03-01 1991-09-02 Brian Gregory Chapman Systeme d'imagerie ponctuelle avec poste de production associe
CA2079803A1 (fr) * 1990-04-03 1991-10-04 Washington Odur Ayuko Utilisation de trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou d'affections virales
GB9103075D0 (en) * 1991-02-13 1991-03-27 Washington Odur Ayuko Trinitrobenzene derivatives and their therapeutic use
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9427584A2 *

Also Published As

Publication number Publication date
HU9503327D0 (en) 1996-01-29
MA23202A1 (fr) 1994-12-31
WO1994027584A3 (fr) 1995-05-26
JPH08510468A (ja) 1996-11-05
AU6729794A (en) 1994-12-20
CA2163459A1 (fr) 1994-12-08
FI955605L (fi) 1996-01-22
CN1124012A (zh) 1996-06-05
OA10196A (en) 1996-12-18
NO954702L (no) 1996-01-22
HUT77764A (hu) 1998-08-28
WO1994027584A2 (fr) 1994-12-08
SK145795A3 (en) 1996-10-02
BR9406548A (pt) 1996-01-02
AP9400647A0 (en) 1995-11-20
IL109712A0 (en) 1994-08-26
FI955605A0 (fi) 1995-11-21
BG100242A (bg) 1996-07-31
CZ307395A3 (en) 1996-06-12
FI955605A7 (fi) 1996-01-22
NO954702D0 (no) 1995-11-21
DZ1781A1 (fr) 2002-02-17

Similar Documents

Publication Publication Date Title
WO1994027584A2 (fr) Medicaments d'arylation
DK2125697T3 (en) POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF RETINOIDS AND RETINOID SIMILAR COMPOUNDS WITH VERY HIGH SKIN PENETRATION
Kapadia et al. Aminonaphthoquinones—a novel class of compounds with potent antimalarial activity against plasmodium falciparum
JP2000119188A (ja) ヒト免疫不全ウイルスおよびその他感染性疾患の抗菌予防と治療
de Araújo et al. Evaluation on the leishmanicidal activity of 2-N, N′-dialkylamino-1, 4-naphthoquinone derivatives
EP1001759B1 (fr) Inhibition virale au moyen d'alcools, alcanes, acides gras et amides a chaine longue
GB2284153A (en) Therapeutic arylating agents
El-Hag et al. Antimicrobial properties of Lawsonia inermis (henna): a review
EP1016405A2 (fr) Médicaments d'arylation
Turjanmaa et al. Isotretinoin treatment of rosacea
Peixoto et al. Epoxy-α-lapachone (2, 2-Dimethyl-3, 4-dihydro-spiro [2H-naphtho [2, 3-b] pyran-10, 2′-oxirane]-5 (10H)-one): a promising molecule to control infections caused by protozoan parasites
AP575A (en) Anti viral and anti cancer agents.
GB2288333A (en) Benzoic acid containing chloro and or nitro groups for cancer or viral therapy
Piraccini Drug‐induced nail disorders
Micheletti et al. Antiprotozoal Activity of Xanthone Derivatives
Bhale Chapter-6 Exploring Chalcone Hybrids as Key Structures in the Search for Anti-Malarial Drugs
Fidalgo Essential oil from Chenopodium ambrosioides as a promising antileishmanial agent
Bertam A Preliminary Study on the Anti-‐Proliferative Activity of Hydroquinone (benzene-‐1, 4-‐diol) Against Promastigotes of Leishmania major and Leishmania tropica in vitro
EP3970714A1 (fr) Composition à usage topique pour la thérapie photodynamique
Barbosa et al. Evaluation of photodynamic antimicrobial therapy (PACT) against trypomastigotes of Trypanosoma cruzi: In vitro study
Strobi et al. SCRIPTAID AND SUBEROYLANILIDE HYDROXAMIC ACID ARE HISTONE DEACETYLASE INHIBITORS WITH POTENT ANTI-TOXOPLASMA GONDII ACTIVITY IN VITRO.
CA2421622A1 (fr) Activateurs du recepteur de l'insuline destines au traitement de troubles metaboliques chez des humains resultant d'un traitement contre l'infection a vih avec des inhibiteurs de la vih protease
FELDMANN Condensations of Glucamine with Aromatic Compounds
WO2005092355A1 (fr) Phytocomposition pour le traitement de maladies articulaires
Lago et al. Natural Products from Plants as Potential Leads as Novel Antileishmanials: A Preclinical Review

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAX Requested extension states of the european patent have changed

Free format text: SI PAYMENT 951221

RAX Requested extension states of the european patent have changed

Free format text: SI PAYMENT 951221

17Q First examination report despatched

Effective date: 19960719

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RADOPATH PHARMACEUTICALS INTERNATIONAL LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20000403